117 related articles for article (PubMed ID: 38279418)
1. Bcl-2 expression in cell lines breast cancer and death program.
Janaghard MS; Soleimani S; Movafagh A; Motallebi M; Mousavi SA; Moghadam AAS; Moghadam VE; Khosravi A; Mirzaei HR; Mousavi SAR; Aziziaram Z; Sun C
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):277-285. PubMed ID: 38279418
[TBL] [Abstract][Full Text] [Related]
2. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD
Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054
[TBL] [Abstract][Full Text] [Related]
3. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
4. [The effects of antisense oligonucleotides bcl-2/bcl-xl and bcl-2 on proliferation and apoptosis of breast cancer cells].
Ma C; Xie JW; Kuang AR; Huang R; Tang GS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):780-3. PubMed ID: 19950582
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
6. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
[TBL] [Abstract][Full Text] [Related]
7. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
8. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.
Nahta R; Yuan LX; Fiterman DJ; Zhang L; Symmans WF; Ueno NT; Esteva FJ
Mol Cancer Ther; 2006 Jun; 5(6):1593-601. PubMed ID: 16818519
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
Lilling G; Hacohen H; Nordenberg J; Livnat T; Rotter V; Sidi Y
Cancer Lett; 2000 Dec; 161(1):27-34. PubMed ID: 11078910
[TBL] [Abstract][Full Text] [Related]
10. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations.
Meidan VM; Glezer J; Salomon S; Sidi Y; Barenholz Y; Cohen JS; Lilling G
J Liposome Res; 2006; 16(1):27-43. PubMed ID: 16556548
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
Jiang H; Xia D; Wu LJ; Chen ZD
Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
[TBL] [Abstract][Full Text] [Related]
12. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
[TBL] [Abstract][Full Text] [Related]
13. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
[TBL] [Abstract][Full Text] [Related]
16. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
Joyner DE; Albritton KH; Bastar JD; Randall RL
J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
[TBL] [Abstract][Full Text] [Related]
17. Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy.
Chen T; Xu J; Zhu L; Yan D
Nanoscale; 2023 Jan; 15(4):1914-1924. PubMed ID: 36617999
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide.
Yang JH; Feng F; Qian H; Cheng H
Breast; 2004 Jun; 13(3):227-31. PubMed ID: 15177426
[TBL] [Abstract][Full Text] [Related]
19. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
